Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY21 results · Oct–Dec 2020
Aarti Drugs reported revenue from operations of ₹530.25 crore (up 12.0% from Q3 FY20) and net profit of ₹68.03 crore (up 144.9% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 530.25 | 473.51 | +12.0% | 578.11 | −8.3% |
| Other income | 2.00 | 0.25 | +700.0% | 0.29 | +589.7% |
| Total income | 532.25 | 473.76 | +12.3% | 578.40 | −8.0% |
| Profit before tax | 90.37 | 43.08 | +109.8% | 97.12 | −7.0% |
| Net profit for the period | 68.03 | 27.78 | +144.9% | 75.27 | −9.6% |
| Attributable to shareholders of the company | 68.04 | 27.78 | +144.9% | 75.27 | −9.6% |
| EPS, basic (₹) | 7.30 | 11.92 | not comparable | 32.30 | not comparable |
| Net margin (%) | 12.8 | 5.9 | 13.0 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 472.10 | 415.61 | +13.6% | 515.16 | −8.4% |
| Other income | 4.07 | 0.13 | 31x | 0.26 | 16x |
| Total income | 476.17 | 415.74 | +14.5% | 515.42 | −7.6% |
| Profit before tax | 85.16 | 39.50 | +115.6% | 90.28 | −5.7% |
| Net profit for the period | 64.66 | 26.75 | +141.7% | 69.78 | −7.3% |
| EPS, basic (₹) | 6.94 | 11.48 | not comparable | 29.95 | not comparable |
| Net margin (%) | 13.7 | 6.4 | 13.5 |
Consolidated
- Filed with BSE
- 27 Jan 2021, 08:34 IST
- Board meeting
- 25 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2021, 08:34 IST
- Board meeting
- 25 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Audited
- Source
- XBRL filing on BSE